| mavoglurant (STP7) / STALICLA |
NCT00414856: Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux |
|
|
| Completed | 1 | 34 | Europe | AFQ056 | Novartis | Gastroesophageal Reflux Disease | | | | |
NCT00414752: Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking |
|
|
| Completed | 1 | 36 | Europe | AFQ065 | Novartis | Smoking Abstinence | | | | |
NCT01442259: An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects |
|
|
| Completed | 1 | 48 | Europe | AFQ056 | Novartis Pharmaceuticals | Mild Moderate, or Severe Renal Impairment | 08/11 | 08/11 | | |
2010-019353-18: Two-period, single-dose pharmacokinetic study in male adolescent patients with Fragile X Syndrome (FXS). |
|
|
| | 1 | | NA | AFQ056, AFQ056, | Novartis Pharma Services AG, Novartis Pharma Services AG | Fragile X Syndrome | | | | |
NCT01456663: A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects |
|
|
| Completed | 1 | 118 | Europe, US | AFQ056 | Novartis Pharmaceuticals | Hepatic Impairment | 07/12 | 07/12 | | |
NCT01482143 / 2011-004867-65: Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS) |
|
|
| Completed | 1 | 21 | Europe, US | AFQ056 | Novartis Pharmaceuticals | Fragile X Syndrome | 10/13 | 10/13 | | |
2011-000365-12: A study to determine the blood concentration of AFQ056 drug after taking a single dose, for 2 pediatric formulations in fed or fasted adult subjects |
|
|
| Completed | 1 | 30 | Europe | AFQ056, AFQ056, | Novartis Pharma Services AG, Novartis Pharma AG | Not Applicable. This is a PK study (including evaluation of food effect). | | 07/11 | | |
NCT03341715: Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN |
|
|
| Completed | 1 | 18 | US | Mavoglurant (AFQ056), Placebo | Yale University | Familial Alcoholism Vulnerability | 11/19 | 11/19 | | |
NCT04771143: Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056 |
|
|
| Withdrawn | 1 | 0 | NA | AFQ056, Placebo | Novartis Pharmaceuticals, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 01/22 | 01/22 | | |
| Completed | 1 | 34 | US | Mavoglurant, Placebo | Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Drinking | 07/23 | 07/23 | | |
| Recruiting | 1 | 20 | US | STP7 (mavoglurant) or Placebo, Cocaine, Saline infusion | Stalicla SA, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 09/24 | 09/24 | | |
NCT05203965: Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant |
|
|
| Recruiting | 1 | 80 | US | Mavoglurant (AFQ056), Placebo | Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Familial Alcoholism Vulnerability | 06/25 | 06/25 | | |
